Cited by 341Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsAntiplatelet Therapy and Cardiovascular Diseases

The DOI matches its Crossref record; 66 of the 69 references it cites were found in a registry or an index.

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trials

Open access

Costa, João, Borges, Margarida, David, Cláudio, Carneiro, António Vaz·2006·BMJ

DOI 10.1136/bmj.38793.468449.aePMC PMC1459619

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVE: To evaluate the clinical benefit of lipid lowering drug treatment in patients with and without diabetes mellitus, for primary and secondary prevention. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Cochrane, Medline, Embase, and reference lists up to April 2004. STUDY SELECTION: Randomised, placebo controlled, double blind trials with a follow-up of at least three years that evaluated lipid lowering drug treatment in patients with and without diabetes mellitus. DATA EXTRACTION: Two independent reviewers extracted data. The primary outcome was major coronary events defined as coronary heart disease death, non-fatal myocardial infarction, or myocardial revascularisation procedures. RESULTS: Twelve studies were included. Lipid lowering drug treatment was found to be at least as effective in diabetic patients as in non-diabetic patients. In primary prevention, the risk reduction for major coronary events was 21% (95% confidence interval 11% to 30%; P < 0.0001) in diabetic patients and 23% (12% to 33%; P = 0.0003) in non-diabetic patients. In secondary prevention, the corresponding risk reductions were 21% (10% to 31%; P = 0.0005) and 23% (19% to 26%; P < or = 0.00001). However, the absolute risk difference was three times higher in secondary prevention. When results were adjusted for baseline risk, diabetic patients benefited more in both primary and secondary prevention. Blood lipids were reduced to a similar degree in both groups. CONCLUSIONS: The evidence that lipid lowering drug treatment (especially statins) significantly reduce cardiovascular risk in diabetic and non-diabetic patients is strong and suggests that diabetic patients benefit more, in both primary and secondary prevention. Future research should define the threshold for treatment of these patients and the desired target lipid concentrations, especially for primary prevention.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1136/bmj.38793.468449.ae

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled Study
Toprak, Ö., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,772
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07037-8 · Cited by 8,247
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261

Show all 69 references

Research works printed but not linked: 1

Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993;2:121-45.

Sorted by citations

Items 201–300 of 341

Treating dyslipidaemia in the setting of diabetes mellitus and cardiovascular disease: a less commonly perceived therapeutic perspective in clinical practice
Varughese, G. I., & Scarpello, J. H. B. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01011.x · Cited by 6
INTERNATIONAL HEALTH NEWS
Ware, W. R. (2010) · Cited by 6
Predictors of uncontrolled hyperlipidaemia in high-risk ambulatory patients in primary care
Hildemann, S. K., Karmann, B., Pittrow, D., Barho, C., Darius, H., & Bode, C. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802134755 · Cited by 6
Diabetes and lipid lowering: where are we?
Reckless, J. P. D. (2006) · BMJ · doi:10.1136/bmj.332.7550.1103 · Cited by 6
The association between co-morbidity and the use of antidiabetics or adjunctive cardiovascular medicines in Australian veterans with diabetes
Zhang, Y., Vitry, A. I., Caughey, G. E., Roughead, E. E., Ryan, P., Gilbert, A., Shakib, S., & McDermott, R. A. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.10.006 · Cited by 5
Cardiovascular disease risk assessment in patients with obstructive sleep apnoea: clinical utility of the Framingham risk equation for initiating statins
Horwood, F., Gruber, A., Sithole, J., Ali, N., & IDRIS, I. R. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00732.x · Cited by 5
Patient outcomes from 10 years of annual diabetes reviews in New Zealand
Tomlin, A. M., Dovey, S. M., & Tilyard, M. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.09.002 · Cited by 5
Dyslipidemia: Pathogenesis and Management
Ganda, O. P. (2009) · Springer eBooks · doi:10.1007/978-0-387-09841-8_28 · Cited by 5
Adherence to Guidelines at a Stroke Prevention Clinic: A Follow-up Study
Chen, B., Perkins, H., Ehrensperger, E., Minuk, J., Vieira, L., Wein, T. H., & Côté, R. (2019) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2018.352 · Cited by 5
Antioxidant Effects of L-citrulline Supplementation in High-fat Diet- and Dexamethasone-induced Type-2 Diabetes Mellitus in Wistar Rats (Rattus norvegicus)
Hassan-Danboyi, E., Jimoh, A., Alhassan, A., Danboyi, T., Mohammed, K. A., Dubo, A. B., Haruna, J., & Yakubu, B. B. (2021) · Nigerian Journal of Experimental and Clinical Biosciences · doi:10.4103/njecp.njecp_4_21 · Cited by 5
Efficacy and Safety of Ezetimibe for Japanese Patients with Dyslipidaemia
Sawayama, Y., Maeda, S., Ohnishi, H., Hayashi, S., & Hayashi, J. (2010) · Clinical Drug Investigation · doi:10.2165/11531530-000000000-00000 · Cited by 5
Should We Be More Aggressive in the Therapy Against Cardiovascular Risk Factors?
Stirban, A. O., & Tschoepe, D. (2008) · Diabetes Care · doi:10.2337/dc08-s254 · Cited by 5
Coronary Heart Disease
Abdelhafiz, A. H. (2009) · Wiley eBooks · doi:10.1002/9780470744093.ch5 · Cited by 5
Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies
Hermans, M. P., Bouénizabila, E., Amoussou-Guénou, D., Ahn, S. A., & Rousseau, M. F. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0226-z · Cited by 4
Glycemic and Cardiovascular Risk Control among Patients with Type 2 Diabetes: A Saudi Tertiary Care Hospital Experience
Alhamwy, R., Hafiz, M., & Abuzied, Y. (2019) · Global Journal on Quality and Safety in Healthcare · doi:10.4103/jqsh.jqsh_14_19 · Cited by 4
The effect of saffron supplementation on glycemic parameters: An overview of systematic reviews
Sadigi, B., Yarani, R., Mirghafourvand‬‬‬‬‬‬‬‬‬‬‬‬‬‬, M., Travica, N., Yousefi, Z., Shakouri, S. K., Ostadrahimi, A., Mobasseri, M., Pociot, F., Sanaie, S., et al. (2022) · Phytotherapy Research · doi:10.1002/ptr.7542 · Cited by 4
Lifetime risk assessment in cholesterol management among hypertensive patients: observational cross-sectional study based on electronic health record data
Tahkola, A., Korhonen, P. E., Kautiainen, H., Niiranen, T., & Mäntyselkä, P. T. (2020) · BMC Family Practice · doi:10.1186/s12875-020-01138-5 · Cited by 4
Position statement of the SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN y SEMFYC
Huelgas, R. G., Peralta, F. G., Fernández, L. C., Galve, E., Casanueva, F. F., Puig‐Domingo, M., Bravo, J. J. M., Beltrán, D. O., Muñoz, J. E., Torre, E. L. M., et al. (2015) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2015.09.004 · Cited by 4
The MERCURY I open-label extension study — subgroup analysis in patients with diabetes
Schuster, H., Palmer, M. K., & Ditmarsch, M. (2008) · The British Journal of Diabetes · doi:10.1177/14746514080080030601 · Cited by 4
Management of Cardiovascular Risk Associated with Insulin Resistance, Diabetes, and the Metabolic Syndrome
Mehta, A. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2143 · Cited by 3
ATORVASTATIN INFLUENCE ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Ionică, F. E., Nikos, R. F., Tărâţă, M., Popescu, F., & Davila, C. (2010) · Cited by 3
Serum Heparanase Level Is Decreased in Stable Coronary Artery Disease
Gürbüz, A. S., Öztürk, S., Efe, S. Ç., Yılmaz, M. F., Yanik, R. E., Yaman, A. E., & Kırma, C. (2019) · Medical Principles and Practice · doi:10.1159/000503085 · Cited by 3
Prescribing patterns of statins and associated factors among type 2 diabetes mellitus patients in Africa: A systematic review and meta-analysis
Tassew, W. C., Ferede, Y. A., & Zeleke, A. M. (2024) · Metabolism Open · doi:10.1016/j.metop.2024.100297 · Cited by 3
Evaluation of the Prevalence and Pattern of Dyslipidemia in Newly Detected Type 2 Diabetes Mellitus Patients and Nondiabetic Controls
Shekhawat, V. S., Behera, V., Nayak, A. K., Kamal, K. D., Ramamoorthy, A., Kumar, R. R., & Roy, S. K. (2024) · Journal of Marine Medical Society · doi:10.4103/jmms.jmms_160_23 · Cited by 3
Quality of care for type 2 diabetes mellitus in Tripoli Medical Center: a retrospective study of 628 patients
El-Shareif, H. J. (2018) · Clinical Diabetology · doi:10.5603/dk.2017.0033 · Cited by 4
Puesta al día en el manejo de las dislipidemias
Sonia Kunstmann, F., & Renata, D. G. K. (2012) · Revista Médica Clínica Las Condes · doi:10.1016/s0716-8640(12)70368-1 · Cited by 3
Association of APOA5 −1131T>C Polymorphism and Serum Lipid Levels in Patients with Type 2 Diabetes
Ćelap, I., Šimundić, A.-M., Nikolac, N., Kačkov, S., & Katalinić, D. (2013) · DNA and Cell Biology · doi:10.1089/dna.2013.2099 · Cited by 3
Development of an Interactive Model of the Burden of Future Coronary Heart Disease From an Employer Perspective
Lang, K. M., Korn, J. R., Simko, R. J., Zachry, W., Patel, N. V., Nair, R., & Menzin, J. (2010) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0b013e3181ebbb3d · Cited by 3
Lipid-Modifying and Antiatherosclerotic Drugs
Gotto, A. M., & Opie, L. H. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-6158-8.50015-0 · Cited by 3
Struck by ACCORD
Mcgrane, D., & Fisher, M. (2008) · Practical Diabetes · doi:10.1002/pdi.1227 · Cited by 3
Lipid lowering drugs in diabetes: Lipid lowering has ophthalmic benefits
Sheth, H. G., Aslam, S. A., & Davies, N. (2006) · BMJ · doi:10.1136/bmj.332.7552.1272-b · Cited by 3
The New Modern Medicine
Fuller, J. (2025) · doi:10.1093/9780190066178.001.0001 · Cited by 3
The Ethics of Prescribing Medications to Older People
Couteur, D. G. L., Kendig, H. L., Naganathan, V., & McLachlan, A. J. (2010) · Springer eBooks · doi:10.1007/978-1-60327-457-9_3 · Cited by 2
From the Library
(2002) · British Journal of Ophthalmology · doi:10.1136/bjo.86.10.1195 · Cited by 2
Drugs in the Primary and Secondary Prevention of Coronary Artery Disease
Kappagoda, C. T., Amsterdam, E. A., & WENGER, N. K. (2014) · Springer eBooks · doi:10.1007/978-3-642-37393-0_55-1 · Cited by 2
Variations in lipid screening frequency in family medicine patients with cardiovascular risk factors
Doğaner, Y. Ç., Rohrer, J. E., Angstman, K. B., Merry, S. P., & Erickson, J. L. (2014) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12290 · Cited by 2
Effects of thiazolidinediones on the triad of type 2 diabetes mellitus, insulin resistance and cardiovascular disease
Chan, J., Ilag, L. L., & Tan, M. H. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.09.010 · Cited by 2
Epidemiological Aspects of Atherosclerosis in Patients Treated for Acute Atherothrombosis of Extremity Arteries
Rustempašić, N., Totić, D., Djedović, M., Rustempasic, M., & Malešić, N. (2014) · Medical Archives · doi:10.5455/medarh.2014.68.329-331 · Cited by 2
Combination thiazolidinedione and fibrate effect on high-density lipoprotein cholesterol (HDL-C) concentration in a Veterans Affairs patient population
Álvarez, C. A., Russell, N. M., Edwards, K. L., Greene, R. S., Chastain, L. M., Weideman, R. A., & Busti, A. J. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.10.004 · Cited by 2
Encuesta Nacional del Tratamiento y Control Metabólico y de los Factores de Riesgo Cardiovascular de los pacientes con diabetes mellitus tipo 2, atendidos por especialistas en Medicina Interna
Escobedo, J., Reyes, J. R., Gómez, L. F., Gracida, L. O., Melgar, P. H., Madrigal, J. C., Guerra, J. L. A., Pichardo, L. O. V., Rosales, J. A. V., Landaverde, A. R., et al. (2010) · Medicina Interna de México · Cited by 2
Dyslipidemia and Diabetes
Gouni‐Berthold, I., Betteridge, D., & Krone, W. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-28 · Cited by 2
Assessing the effect of socioeconomic factors on prevalence of dyslipidemia among iranian adult population; district level analysis from 2016 STEPS national study using small area estimation
Soleimani, H., Ghasemi, E., Moghaddam, S. S., Azadnajafabad, S., Rezaei, N., Masinaei, M., Naderimagham, S., Rezaei, N., Malekpour, M., Keykhaei, M., et al. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-022-01027-x · Cited by 2
Diabetes and Cardiovascular Disease
Bertoni, A. G., & Goff, D. C. (2010) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195317060.003.0009 · Cited by 2
Blood Lipid Abnormalities
Bilous, F. R., & Donnelly, R. (2010) · Wiley eBooks · doi:10.1002/9781444391374.ch18 · Cited by 2
Statins for primary prevention in type 2 diabetes
(2006) · Drug and therapeutics bulletin · doi:10.1136/dtb.2006.44857 · Cited by 2
ANTIOXIDANT VITAMIN STATUS IN TYPE 1 DIABETES MELLITUS PATIENTS
Ahmad, M. I., Khan, M. A., & Khan, A. S. (2011) · Journal of Postgraduate Medical Institute · Cited by 1
Hydroxymethylglutaryl-CoA reductase inhibitors (statins) for the treatment of sepsis
Pertzov, B., Trestioreanu, A. Z., Eliakim‐Raz, N., Yahav, D., & Leibovici, L. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011329 · Cited by 1
Retracted
Dislipidemia en medicina interna
Lahsen, R. (2010) · Medwave · doi:10.5867/medwave.2010.04.4497 · Cited by 1
Contemporary treatment strategies for Type 2 diabetes-related macrovascular disease
Walker, A. M., Cubbon, R. M., & Kearney, M. T. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.941356 · Cited by 1
L’intérêt démontré des statines chez les patients diabétiques de type 2
Vergès, B. L. (2010) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(10)70013-4 · Cited by 1
Prevención primaria con estatinas en diabéticos
Bosch, M., & Danés, I. (2007) · Medicina Clínica · doi:10.1157/13109121 · Cited by 1
Is diabetes a coronary artery disease equivalent?
Turgeon, R. D., Banh, H. L., & Korownyk, C. S. (2013) · Europe PMC (PubMed Central) · Cited by 1
Diabetes and Cardiovascular Disease Intensive Glucose Lowering and Cardiovascular Disease Prevention in Diabetes Reconciling the Recent Clinical Trial Data
Mazzone, T. (2016) · Cited by 1
DYSLIPIDEMIAS
Murphy, M. S., & O’Brien, T. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50027-5 · Cited by 2
The Effect of Atherosclerotic Load on Transmetatarsal Amputation Failure in Patients with Diabetic Foot
Çildağ, M. B., Şahin, T., Ceylan, E., & Şavk, Ş. Ö. (2022) · Meandros Medical And Dental Journal · doi:10.4274/meandros.galenos.2022.68815 · Cited by 1
The Gulf Achievement of Cholesterol Targets in Out-Patients Study (GULF ACTION): Design, Rationale, and Preliminary Results
Albackr, H. B., Waili, K. A., Almahmeed, W. A., Jarallah, M. A., Amin, M., Al‐Rasadi, K., Batais, M. A., Almigbal, T. H., Youssef, A. A., AlGhamdi, M. A., et al. (2023) · Current Vascular Pharmacology · doi:10.2174/1570161121666230710145604 · Cited by 1
The understanding of terms in evidence-based medicine: a pilot study
Brooks, A. P., Kibble, S. E., & Alderson, S. (2009) · European Diabetes Nursing · doi:10.1002/edn.143 · Cited by 1
Dyslipidémie
Mancini, G. B. J., Hegele, R. A., & Leiter, L. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.015 · Cited by 1
Vascular Complications in Type 2 Diabetes
Chen-Ku, C. H. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_37 · Cited by 1
Atherogenesis, coronary heart disease and insulin resistance syndrome in diabetes
Zafrir, B., & Plutzky, J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch70 · Cited by 1
Risque cardiovasculaire résiduel du patient diabétique de type 2
Vergès, B. L. (2010) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(10)70082-1 · Cited by 1
Lipid lowering drugs in diabetes: Absolute risk reduction is what counts
LEWIS, L. S. (2006) · BMJ · doi:10.1136/bmj.332.7552.1272-a · Cited by 1
Management of diabetic dyslipidemia: doing the right thing
Brinton, E. A. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0293 · Cited by 1
Lipid lowering drugs in diabetes: Abstract was misleading
van Driel, M., & Chevalier, P. (2006) · BMJ · doi:10.1136/bmj.332.7552.1272 · Cited by 1
Type 2 diabetes patients: profiles, treatment and daily practice
Zambon, A. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.020 · Cited by 1
Opportunities for preventing diabetes and its cardiovascular complications
van den Bos, G. A. M. (2007) · Cited by 1
Coronary heart disease
Abdelhafiz, A. H. (2017) · Wiley eBooks · doi:10.1002/9781118954621.ch7 · Cited by 1
The role of insulin and IGF2 signalling on metabolic pathways in prostate cancer progression
Lubik, A. A. (2011) · Faculty of Science and Technology; Institute of Health and Biomedical Innovation
Analysing recent time trends in coronary heart disease and type 2 diabetes in the UK
Hardoon, S. L. (2012) · UCL Discovery (University College London)
Medicine on demand, medication patterns and glycemic control in patients with type 2 diabetes
Lamberts, E. J. F. (2013) · Utrecht University Repository (Utrecht University)
Diabetic Nephropathy: A Cardiovascular Risk Factor
Magri, C. J., & Fav, S. (2012) · InTech eBooks · doi:10.5772/25431
Reducing the Risk of Stroke
Gibson, J. M. E., & Jones, S. P. (2019) · Wiley eBooks · doi:10.1002/9781119581161.ch3
Power of the Pill : Views about Cardiovascular Risk and the Risk-reducing Effect of Statins
Lytsy, P. (2011) · Socialmedicinsk tidskrift · doi:10.62607/smt.v87i5-6.43958
Pioglitazon vermindert das kardiovaskuläre Risiko bei Typ-2-Diabetespatienten
Bierwirth, R., Dietlein, M., Franzen, C., Grünerbel, A., Hofmann, C., Merke, J., Lübben, G., & Karagiannis, E. (2008) · Der Diabetologe · doi:10.1007/s11428-008-0326-4
Do we reach target lipid levels in diabetic and non-diabetic patients with previous myocardial infarction?
Aleksic, E., Stamenković, R., Lapčević, M., Deljanin-Ilić, M., Djordjevic, D. B., & Tasic, I. S. (2011) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh1102030a
Quelle place pour l’aspirine en prévention cardiovasculaire primaire chez le diabétique en 2010 ?
Dillinger, J., Sidéris, G., & Henry, P. (2010) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(10)70092-4
Diabetic dyslipidaemia: the role of niacin derivatives lack long-term outcome data
Varughese, G. I., & Scarpello, J. H. B. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01142.x
Improving the Prognosis in Patients With Diabetes: What Will ADVANCE Tell Us?
Gupta, A. K., & Poulter, N. R. (2007) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2007.04.006
Pré-eclâmpsia: "estado hipovolêmico" ou "conteúdo ajustado ao continente?"
Ruano, R., & Zugaib, M. (2006) · Revista da Associação Médica Brasileira · doi:10.1590/s0104-42302006000400010
Una mujer diabética con dislipemia
Beltrán, D. O., Gil-Guillén, V. F., Andrés, F., & Carratalá‐Munuera, C. (2009) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(09)72326-1
Diabetes mellitus, myocardaandoening en medicamenteuze verlaging van vetten in bloed
Vingerhoeds, A. C. M. (2006) · Medisch-Farmaceutische Mededelingen · doi:10.1007/bf03058861
Qual o número de pacientes diabéticos tipo 2 necessário a tratar para se evitar um evento coronariano?
Bernardo, W. M., & Castro, L. C. (2006) · Revista da Associação Médica Brasileira · doi:10.1590/s0104-42302006000400011
Review: The role of fenofibrate in reducing cardiovascular risk in type 2 diabetes
Pedro‐Botet, J. (2008) · The British Journal of Diabetes · doi:10.1177/14746514080080010601
Documento de consenso de la Red de Grupos de Estudio de la Diabetes en Atención Primaria de la Salud) sobre el tratamiento de la dislipidemia en la diabetes tipo 2 en prevención primaria
Rodríguez‐Poncelas, A., Sánchez, J. J. A., Cosmea, A. Á., Cumplido, A. S., & Baile, J. L. T. (2013) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2013.02.004
ESTUDIO DOBLE CIEGO, DE DOBLE ENGANO, FASE IV, ALEATORIZADO, MULTICENTRICO, DE GRUPOS PARALELOS, CONTROLADO CON PLACEBO PARA EVALUAR EL EFECTO DE ROSUVASTATINA SOBRE LOS NIVELES DE TRIGLICERIDOS EN PACIENTES HIPERTRIGLICERIDEMICOS MEXICANOS
Fuentes, M., & Isidro, G. (2012)
Original Article: Epidemiology Is diabetes a coronary risk equivalent? Systematic review and meta-analysis
Bulugahapitiya, U., Siyambalapitiya, S., Sithole, J., & IDRIS, I. R. (2009)
Estatinas y diabetes
de Tuero, G. C., & Rodríguez‐Poncelas, A. (2010) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2010.08.002
Guía práctica de prevención cardiovascular
Araújo, O., Ardanaz, N., Bachman, R., Bianco, E., Burdiat, G., Arnesto, O. D., González, G., Lado, M., Lagos, M. E., Layerle, B., et al. (2009) · Revista Uruguaya de Cardiología
L’utilisation de l’atorvastatine pour la prévention primaire des maladies cardiovasculaires chez les patients diabétiques de type II
Marin, J. (2006) · Pharmactuel
Preventing cardiovascular disease in type 2 diabetes: Where do things stand with glycemic control? Part two
Chait, A. (2009) · Current Diabetes Reports · doi:10.1007/s11892-009-0003-z
Review: Statin plus thiazolidinedione use in patients with diabetes at high cardiovascular risk
Erdmann, E. (2007) · The British Journal of Diabetes · doi:10.1177/14746514070070050301
Optimizing Cardiovascular Outcomes in Diabetes Mellitus: A Call to Action
Sobel, B. E. (2007)
Razão triglicerídios / HDL-colesterol como preditor do perfil de subclasses de lipoproteínas
Toé, D., & Fernandes, T. (2007) · Americanae (AECID Library)
Aggressive Lipid Lowering Is Especially Helpful in Diabetics
Marton, K. I. (2006) · Journal watch · doi:10.1056/jg200606270000007
PUESTA AL DÍA EN EL MANEJO DE LAS DISLIPIDEMIAS
Medicina, F. D. (2012)
Сосудистые осложнения сахарного диабета 2 типа за гранью гликемического контроля
Yu, D. T. (2010) · CyberLeninK (CyberLeninka)
Risk factors for dyslipidemia among hypertensive patients attending the laboratory of the european Gaza hospital: case control study
Zohry, H. A., Aljeesh, Y. I., & Abusalem, S. (2014)
Two Adults With Hypertriglyceridemia: How should one manage these persons?(#).
Jayasinghe, S. H. (2008) · Europe PMC (PubMed Central)
PREGUNTAS Y RESPUESTAS EN FARMACOLOGÍA CLÍNICA Prevención primaria con estatinas en diabéticos
Bosch, M., & Danés, I. (2016)
Effects of Statin therapy at high doses versus low doses in an atherosclerotic rabbit model
봉성경 (2018)

Authors: Costa, J., Borges, M., David, C., & Carneiro, A. V.
Affiliations: University of Lisbon (PT)
Hospital de Santa Maria (PT)
ORCID: Costa, João
Carneiro, António Vaz
Venue: BMJ
Publisher: BMJ
Published: 2006-04-03
Volume: 332
Issue: 7550
Pages: 1115-1124
ISSN: 0007-1447 (ISSN-L)
0959-8138
1468-5833
DOI: 10.1136/bmj.38793.468449.ae
PMC: PMC1459619
OpenAlex: W2141819264
Cited by: 340
References: 69
Citations by year: 2026: 1 · 2025: 14 · 2024: 7 · 2023: 6 · 2022: 13 · 2021: 9 · 2020: 8 · 2019: 8 · 2018: 10 · 2017: 6 · 2016: 12 · 2015: 13 · 2014: 20 · 2013: 24 · 2012: 18
FWCI: 7.90
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.bmj.org/licenses/tdm/1.0/terms-and-conditions.html (tdm)
Locations: BMJ (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
HighWire Press Open Archive (submittedVersion)
Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Keywords: lipid-lowering drugs, statins, diabetes mellitus, coronary artery disease, major coronary events, primary prevention, secondary prevention, cardiovascular risk reduction, myocardial infarction, coronary revascularization, lipid lowering
MeSH terms: Hypolipidemic Agents, Coronary Disease, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Humans, Lipids, Myocardial Infarction, Myocardial Revascularization, Risk Factors, Randomized Controlled Trials as Topic, Treatment Outcome, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks